The FDA just announced at the ACC that it will be convening a panel to review the merits of keeping Abbott’s Tricor on the market. The ACCORD study was negative for the drug showing no efficacy and also showing several safety signals (renal and HTN). Recall, ABT recently acquired the European partner for Tricor and Trilipx, Solvay, for $6.6 Billion USD.
Hat tip: The Healthcare Channel on http://thehcc.tv/
No comments:
Post a Comment